AGEN stock news

AGEN earnings call for the period ending June 30, 2019. Read more
Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019. Read more
Agenus (AGEN) delivered earnings and revenue surprises of -15.15% and 192.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more

Agenus Milestone Triggers $7.5M Payment

11:30am, Thursday, 08'th Aug 2019
LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has accepted the company's IND filing for AGEN2373, a milestone in its partnership Read more
Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read more
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth. Read more
Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same. Read more
AGEN earnings call for the period ending March 31, 2019. Read more
Agenus, Inc. (NASDAQ:AGEN) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Jennifer Buell – Chief Operating Officer Garo Armen – Ch Read more

Agenus +7% on Q1 beat

12:56pm, Thursday, 09'th May 2019
Read more

Agenus beats by $0.41, beats on revenue

11:32am, Thursday, 09'th May 2019
Read more

Proudly made at

ROCKIT